Title of Collaborative Activity: |
NIH Recombinant DNA Advisory Committee |
Description of Collaborative Activity: |
The Recombinant DNA Advisory Committee (RAC) advises the National Institutes of Health on the safe and ethical conduct of basic and clinical research involving recombinant DNA. It reviews protocols and provides recommendations for each protocol to enhance the scientific and ethical design. The RAC also discusses safety data and other emerging issues for the field of gene therapy. This year the RAC hosted a meeting to develop biosafety guidelines for gain-of-function research with H5N1 which led to the amendment of the NIH Guidelines for Research with Synthetic and Recombinant Research. The RAC also hosted a meeting of mid-level investigators to examine the scientific and other challenges that gene therapy will face in the next decade and a meeting to discuss optimization of the design of clinical trials using gene modified T cells in order to realize the potential of this immunotherapy while minimizing the risk to subjects. |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
Year the Collaborative Activity Originated: |
1974 |
NIH Participating Institutes/Centers/Office of the Director: |
NCI, NHGRI, NIAID, NINDS, OD/OSP |
HHS Agency Collaborators on this Activity: |
CDC, FDA, OS |
